Navigation Links
Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months

$14,922 $10,070

Securities available-for-sale 16,740 34,256

Accounts receivable, net 8,536 7,534

Inventories, net 5,455 5,860

Other current assets 1,786 1,499

Total current assets 47,439 59,219

Property and equipment, net 16,235 9,570

Other intangible assets, net 2,631 428

Goodwill 2,650 --

Restricted cash 60 60

Total assets $69,015 $69,277

Liabilities and stockholders' equity

Accounts payable $2,650 $2,643

Accrued compensation 3,547 3,650

Accrued warranty 930 788

Other accrued liabilities 3,285 3,306

Deferred revenue 2,909 2,775

Current portion of long-term debt 213 269

Total current liabilities 13,534 13,431

Long-term debt, net of current portion -- 99

Deferred rent 234 302

Total stockholders' equity 55,247 55,445

Total liabilities and stockholders' equity $69,015 $69,277

(1) The condensed consolidated balance sheet as of December 31, 2006, was

derived from the audited financial statements as of that date.

SOURCE Digirad Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
2. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
3. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
4. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
5. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call
7. Baxa Corporation Launches New Web Site
8. CuraGen Corporation Receives Notification from NASDAQ
9. Healionics Corporation Completes Series A Financing
10. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: ... a seasoned management team and Board, which launched the ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... (Nasdaq: FOLD ) today announced it plans to initiate ... drug in development for the treatment of Pompe Disease. ... pharmacokinetics of AT2220 in muscle tissue in healthy adult subjects. ... to Amicus, proposal for the Phase 1 study and subsequently ...
... PARIS, September 30 , ... to Achieve Similar, Well,Tolerated Glycemic Control Versus Lantus(R) , ... ) announced today results of a,head-to-head study providing further evidence ... [rDNA] injection) compared,to twice-daily insulin detemir. The study was presented ...
... John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, ... Institute for Cancer Research (OICR) led a team of ... NEBNext(TM) DNA Sample Prep Reagents for use with OICR,s ... evaluation, "We are constantly striving for the best quality ...
Cached Biology Technology:Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 3Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing 2
(Date:7/9/2014)... about the prevalence of antibiotic-resistant illness, Case Western ... to disabling disease: blocking bacteria,s access to iron ... bacterial siderophore, a small molecule, captures iron from ... as well as how the body launches ... findings appear in a recent edition of ...
(Date:7/9/2014)... may be able to cope with the rising salinity of ... Arctic today is best known for its tundra and polar ... to 38 million years ago during what is known as ... huge temperate forest with brackish water, home to a variety ... and giant tortoises. Much of what is known about the ...
(Date:7/9/2014)... but often can be defeated with antibiotics and then ... Now, scientists have built a new weapon against such pathogens ... journal ACS Applied Materials & Interfaces , their study ... them than medicine alone. , David Leong, Jianping Xie and ... undetectable in the human body or in places that antibiotics ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... compound found in green tea shows great promise for ... tumors and a deadly congenital disease. The discovery ... Dr. Thomas Smith at The Donald Danforth Plant Science ... Philadelphia. Their findings are published in the recent article, ...
... A research team led by St. Jude Children,s ... for treatment of the childhood eye tumor retinoblastoma. Their ... cancer,s cellular origins are as scrambled as the developmental ... cancers that resemble a particular type of cell, researchers ...
... New research suggests that blood stem cells can be involved ... caused by the abnormal proliferation of mature cells. The study, ... the journal Cancer Cell , may guide future strategies ... CLL is a cancer of a type of mature ...
Cached Biology News:Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors 2Childhood eye tumor made up of hybrid cells with jumbled development 2Childhood eye tumor made up of hybrid cells with jumbled development 3Stem cells central to pathogenesis of mature lymphoid tumors 2
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Request Info...
... labware. Waterproof, moisture-proof film prevents sample ... be folded repeatedly and twisted around ... at 21C (70F), wrapping film increases ... removed, film only partially returns to ...
Biology Products: